Overactive Bladder Articles & Analysis
11 news found
BlueWind Medical, in preparation for commercialization of the RENOVA product line, announces the hiring of key positions within the organization. Vice President of Sales Mike Ruger, Vice President of Marketing Sandra Muhlfeld, and Vice President of Human Resources Lisa Mead. BlueWind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment ...
Neuspera Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial (SANS-UUI), a single-arm study that will enroll 145 patients at 25 sites globally. The study will evaluate the safety and efficacy of Neuspera’s Nuvella™ system designed to treat overactive bladder ...
“With the recent completion of enrollment in the OASIS pivotal study, and the potential for FDA marketing clearance in 2023, we are preparing for commercialization and our next phase of corporate growth”, said Dan Lemaitre, Chairman and CEO of BlueWind Medical. “We believe that RENOVA’s minimally invasive and patient centric approach to the treatment of Overactive Bladder ...
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and CEO of ...
Bluewind Medical, Ltd., developer of the innovative RENOVA™ iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced it will be participating in the 33rd Annual Virtual Healthcare Conference organized by Piper Sandler on Nov 29th – Dec 2nd, 2021. As part of the conference, a pre-recorded conversation with Daniel Lemaitre, Chairman and ...
Bluewind Medical, Ltd., developer of the innovative RENOVA iStim implantable neuromodulation device for treatment of urinary urgency incontinence, today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in the United States. OASIS is a ...
Neuspera Medical Inc., a clinical stage, private venture capital backed neuromodulation company, today announced the closing of the company’s $65 million series C equity financing. The Series C round was co-led by Vertex Ventures HC and Treo Ventures. Lori Hu, a Managing Director at Vertex Ventures HC and Mudit K. Jain, Ph.D. Managing Partner, Treo Ventures, joined the Board of Directors. ...
Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of Directors. Mr. Dearen currently serves as the President and Chief Financial Officer of Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology ...
BlueWind Medical, a medical device company developing minimally invasive neurostimulation devices, announced today the appointment of Kerry Nelson to the company’s Board of Directors. Nelson is a successful medical device investor and fund manager who has launched and managed healthcare focused investment funds. Over the course of her career, she has counseled public and private medical ...
Clinical investigators in the OverActive Bladder Stimulation System Study (OASIS) of the RENOVA iStim system, Drs. Becky McCrery and Emily Kean at Adult Pediatric Urology & Urogynecology in Omaha implanted the first U.S. patient in this international clinical study. The RENOVA iStim system is an investigational device designed to reduce urinary urge leakage and improve OAB symptoms. ...
BlueWind Medical announced today that enrollment has commenced at U. S. sites in the Pivotal Clinical Trial of the RENOVA iStim™ implantable tibial neuromodulation System (RENOVA) for the treatment of Overactive Bladder (OAB) following conditional Investigative Device Exemption (IDE) approval by the U.S. Food and Drug Administration (FDA). There are approximately 40 million adults in the ...